Burning Rock Biotech (BNR) EBITDA (2019 - 2025)

Burning Rock Biotech's EBITDA history runs 7 years deep, the most recent figure standing at -$2.5 million for Q4 2025.

• In Q4 2025, EBITDA rose 75.84% year-over-year to -$2.5 million; the TTM figure through Dec 2025 stood at -$8.3 million (up 82.41% YoY), while the FY2025 annual figure was -$8.5 million, up 81.92% from the prior year.
• EBITDA was -$2.5 million for Q4 2025 at Burning Rock Biotech, up from -$2.6 million in the prior quarter.
• In the past five years, EBITDA ranged from a high of -$1.4 million in Q2 2025 to a low of -$43.3 million in Q4 2021.
• Historically, EBITDA has averaged -$20.8 million across 5 years, with a median of -$23.6 million in 2021.
• The sharpest annual moves came in 2021 and 2025: EBITDA slumped 307.26% in 2021, then soared 90.58% in 2025.
• A 5-year view of EBITDA shows it stood at -$43.3 million in 2021, then advanced by 25.59% to -$32.2 million in 2022, then gained by 27.75% to -$23.3 million in 2023, then jumped by 55.68% to -$10.3 million in 2024, then soared by 75.84% to -$2.5 million in 2025.
• The last three EBITDA figures came in at -$2.5 million (Q4 2025), -$2.6 million (Q3 2025), and -$1.4 million (Q2 2025), per Business Quant data.